{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yan D"],"funding":["National Natural Science Foundation of China"],"pagination":["101488"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12818211"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(1)"],"pubmed_abstract":["Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, however, their use is limited by heterogeneous and unpredictable immune-related adverse events (irAEs), which can progress to life-threatening conditions requiring intensive care unit (ICU) admission. Reliable biomarkers for predicting and stratifying ICU-level irAEs are urgently needed to improve immunotherapy safety and critical care management. Here, we performed comprehensive mass spectrometry-based proteomic profiling to identify plasma biomarkers for the prediction and monitoring of irAEs in 65 patients receiving ICI treatment. Our analysis identified 217 differentially abundant proteins and four co-expression modules related to humoral (antibody-mediated) and cellular (T cell-mediated) immunity spanning mild to "],"journal":["Molecular & cellular proteomics : MCP"],"pubmed_title":["Plasma Proteome-Driven Liquid Biopsy for Individualized Monitoring and Risk Stratification of Immune-Related Adverse Events in Checkpoint Immunotherapy."],"pmcid":["PMC12818211"],"funding_grant_id":["U20A20366","82472198"],"pubmed_authors":["Zhou M","Wang C","Wang D","He X","Yan D","Zhu B","Yu K","Xu J","Xing Q"],"additional_accession":[]},"is_claimable":false,"name":"Plasma Proteome-Driven Liquid Biopsy for Individualized Monitoring and Risk Stratification of Immune-Related Adverse Events in Checkpoint Immunotherapy.","description":"Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, however, their use is limited by heterogeneous and unpredictable immune-related adverse events (irAEs), which can progress to life-threatening conditions requiring intensive care unit (ICU) admission. Reliable biomarkers for predicting and stratifying ICU-level irAEs are urgently needed to improve immunotherapy safety and critical care management. Here, we performed comprehensive mass spectrometry-based proteomic profiling to identify plasma biomarkers for the prediction and monitoring of irAEs in 65 patients receiving ICI treatment. Our analysis identified 217 differentially abundant proteins and four co-expression modules related to humoral (antibody-mediated) and cellular (T cell-mediated) immunity spanning mild to ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T18:10:27.909Z","creation":"2026-06-04T03:11:03.515Z"},"accession":"S-EPMC12818211","cross_references":{"pubmed":["41391830"],"doi":["10.1016/j.mcpro.2025.101488"]}}